Unconfigured Ad
Collapse
Discussion of next-gen sequencing related bioinformatics: resources, algorithms, open source efforts, etc
| Forums | Topics | Posts | Last Post |
|---|
No forums found.
There are no conversations in this channel.
Please log in to your account to view your subscribed posts.
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by laura, 05-09-2011, 04:42 AM
|
35 responses
107,625 views
0 reactions
|
Last Post
by laura
12-05-2013, 02:37 AM
|
||
|
Started by sci_guy, 01-23-2008, 11:19 PM
|
236 responses
684,183 views
1 reaction
|
Last Post
by ECO
12-25-2009, 06:45 PM
|
||
|
Started by ruggedtextile, 11-25-2011, 03:48 AM
|
0 responses
1,742 views
0 reactions
|
Last Post
|
||
|
Started by mattia, 11-25-2011, 02:24 AM
|
0 responses
1,344 views
0 reactions
|
Last Post
by mattia
11-25-2011, 02:24 AM
|
||
|
Started by Orr Shomroni, 11-24-2011, 07:22 AM
|
3 responses
7,855 views
0 reactions
|
Last Post
by cjp
11-25-2011, 01:46 AM
|
||
|
Started by desmo, 11-16-2011, 08:25 AM
|
3 responses
2,767 views
0 reactions
|
Last Post
by desmo
11-25-2011, 01:06 AM
|
||
|
Started by wanguan2000, 11-24-2011, 09:23 PM
|
0 responses
3,304 views
0 reactions
|
Last Post
by wanguan2000
11-24-2011, 09:23 PM
|
||
|
Started by lbragg, 11-23-2011, 08:02 PM
|
1 response
2,606 views
0 reactions
|
Last Post
by lbragg
11-24-2011, 07:41 PM
|
||
|
Started by vinay052003, 11-24-2011, 05:53 PM
|
0 responses
2,869 views
0 reactions
|
Last Post
by vinay052003
11-24-2011, 05:53 PM
|
||
|
Started by StephaniePi83, 11-24-2011, 09:30 AM
|
0 responses
1,285 views
0 reactions
|
Last Post
|
||
|
Started by vinay052003, 11-22-2011, 01:40 PM
|
1 response
2,545 views
0 reactions
|
Last Post
by cjp
11-24-2011, 09:03 AM
|
||
|
Started by neetu, 11-24-2011, 03:17 AM
|
1 response
3,434 views
0 reactions
|
Last Post
by ffinkernagel
11-24-2011, 04:13 AM
|
No topics found.
-
Page of 0
-
Filter
widgetinstance 229 (Webinars) skipped due to lack of content & hide_module_if_empty option.
Recent Articles
Collapse
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
07-20-2026, 11:48 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
-
by SEQadmin2
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...-
Channel: Articles
07-08-2026, 05:17 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, Yesterday, 12:17 PM
|
0 responses
13 views
0 reactions
|
Last Post
by SEQadmin2
Yesterday, 12:17 PM
|
||
|
Started by SEQadmin2, 07-23-2026, 11:41 AM
|
0 responses
14 views
0 reactions
|
Last Post
by SEQadmin2
07-23-2026, 11:41 AM
|
||
|
Started by SEQadmin2, 07-20-2026, 11:10 AM
|
0 responses
23 views
0 reactions
|
Last Post
by SEQadmin2
07-20-2026, 11:10 AM
|